October 11-12, 2019 | Beijing, China
Quanterix : SILVER SPONSORS
Presentation: New Frontiers in CNS Biomarkers Empowered by Single-Molecule Array (SIMOA) Technology
Speaker: Andreas JEROMIN, PhD Scientific and Medical Advisor, Quanterix Corporation
Time and Location TBA
Since 2008, The Clinical Trials on Alzheimer's Disease Conference (CTAD) has held an annual event focused on the development of the next generation of Alzheimer’s disease treatments. Alzheimer's disease is among the most important health concerns worldwide but presents huge challenges.
The goal of the CTAD Asia -China Conference is to bring together Asian leaders on the treatment and management of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues that are essential to the development of the next generation of Alzheimer’s disease treatments.
This CTAD Asia - China Conference will focus largely on how to develop successful AD clinical trials worldwide through workshops on important topics for conducting clinical trials: methodology, database management of clinical trials, biomarkers, patient recruitment, etc. This second edition of the conference is expected to gather at least 250 physicians and researchers in the field of Alzheimer’s Disease.
Use of SIMOA® Technology to Improve Measurement of Critical Biomarkers in CNS disease, allowing for the first the quantification of CNS biomarkers in blood. The presentation will highlight and discuss key studies in neurodegeneration and multiple sclerosis.